Dual-Eligible Medicare Beneficiaries Less Likely to Receive Recommended Chemotherapy
the Cancer Therapy Advisor take:
Patients with cancer who are dual-eligible Medicare beneficiaries are less likely to receive recommended chemotherapy compared to those with other types of supplemental Medicare coverage, according to a recent study published in the Journal of Clinical Oncology.
Joan Warren, PhD, of the National Cancer Institute (NCI) in Bethesda, and fellow colleagues examined 1,200 Medicare patients that were diagnosed with various forms of cancer from 2000 to 2005 as part of a retrospective, observational study. They cross-examined patient data acquired from the NCI’s Patterns of Care Studies with SEER-Medicare data in order to determine supplemental insurance status of each patient.
They found that dual-eligible patients with cancer were significantly less likely to receive chemotherapy compared to those Medicare patients covered under private insurance.
In addition, patients who were only covered under Medicare and saw an oncologist were found to have comparable rates of chemotherapy with Medicare patients who had private insurance.
“With the increasing number of Medicaid patients under the Affordable Care Act, there will be a need for patient navigators and sufficient physician reimbursement so that low-income patients with cancer will have access to oncologists and needed treatment,” the authors concluded.
Patients with cancer who are dual-eligible Medicare beneficiaries are less likely to receive recommended chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Role of miR-125a-5p Clarified in Bladder Cancer
- Bladder Cancer Clinical Features Linked to EGFR and HER-2 Expression
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- A Vegan Diet and Cancer
- The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear